Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026)
Palvella Therapeutics' (PVLA) quarterly Retained Earnings came in at -$151.2 million in Q1 2026, down 5039900.0% year-on-year from N/an in Q1 2025, and down 11.63% on a QoQ basis from -$135.4 million in Q4 2025.
Palvella Therapeutics (PVLA) Retained Earnings (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Retained Earnings data on file, last reported at -$151.2 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 5039900.0% year-over-year to -$151.2 million in Q1 2026; TTM through Mar 2026 was -$151.2 million, a 5039900.0% decrease from a year earlier, with the FY2025 full-year figure at -$135.4 million, down 4515100.0% from the prior year.
- Retained Earnings for Q1 2026 stood at -$151.2 million, down from -$135.4 million in the prior quarter.
- Over the last five years, Retained Earnings for PVLA reached as high as $342.9 million in Q3 2024 and fell as low as -$323.4 million in Q2 2024.
- Historically, Retained Earnings has averaged -$94.0 million across 5 years, with a median of -$123.4 million in 2025.
- Across the five-year window, Retained Earnings surged 391.24% in 2022 and sank 5039900.0% in 2026, its largest moves.
- Year by year, Retained Earnings stood at -$254000.0 in 2022, then sank by 122104.72% to -$310.4 million in 2023, then surged by 100.0% to $3000.0 in 2024, then plunged by 4515100.0% to -$135.4 million in 2025, then decreased by 11.63% to -$151.2 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$151.2 million in Q1 2026, -$135.4 million in Q4 2025, and $104000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -622,000.00 |
| 10 | Palvella Therapeutics | 1.84 Bn | 1.57 Bn | - | -151.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -151.20 Mn |
| Dec 31, 2025 | -135.45 Mn |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | -111.40 Mn |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 342.92 Mn |
| Jun 30, 2024 | -323.40 Mn |
| Mar 31, 2024 | 342.17 Mn |
| Sep 30, 2023 | -310.40 Mn |
| Jun 30, 2023 | -299.63 Mn |
| Mar 31, 2023 | -303.60 Mn |
| Dec 31, 2022 | -254,000.00 |
| Sep 30, 2022 | -282.32 Mn |
| Jun 30, 2022 | -272.58 Mn |
| Mar 31, 2022 | 953,000.00 |
| Dec 31, 2021 | -257.14 Mn |
| Sep 30, 2021 | -247.61 Mn |
| Jun 30, 2021 | -231.08 Mn |
| Mar 31, 2021 | 194,000.00 |